Compare · CCXI vs OXSQ
CCXI vs OXSQ
Side-by-side comparison of Churchill Capital Corp XI (CCXI) and Oxford Square Capital Corp. (OXSQ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCXI and OXSQ operate in Blank Checks (Finance), so they compete in similar markets.
- OXSQ carries a market cap of $91.8M.
- Over the past year, CCXI is up 8.8% and OXSQ is down 59.0% - CCXI leads by 67.8 points.
- CCXI has been more active in the news (40 items in the past 4 weeks vs 3 for OXSQ).
- CCXI has more recent analyst coverage (8 ratings vs 0 for OXSQ).
Churchill Capital Corp XI
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.
Oxford Square Capital Corp.
Oxford Square Capital Corp. is a business development company, operates as a closed-end, non-diversified management investment company. It is a private equity and mezzanine firm. The firm invests in both public and private companies. It invests in secured and unsecured senior debt, subordinated debt, junior subordinated debt, preferred stock, common stock and syndicated bank loans. The firm primarily invests in debt and/or equity securities of technology-related companies that operate in the computer software, Internet, information technology infrastructure and services, media, telecommunications and telecommunications equipment, semiconductors, hardware, technology-enabled services, semiconductor capital equipment, medical device technology, diversified technology, and networking systems sectors. It concentrates its investments in companies having annual revenues of less than $200 million and a market capitalization or enterprise value of less than $300 million. The firm invests between $5 million and $30 million per transaction. It seeks to exit its investments within 7 years. It serves as the investment adviser to TICC. Oxford Square Capital Corp., formerly known as TICC Capital Corp., was founded in 2003 and is headquartered in Greenwich, Connecticut.
Latest CCXI
- Chief Operating Officer Hunter Jennifer was granted 3,220,699 stock options (SEC Form 4)
- Officer Lang Anastasia was granted 2,760,599 stock options (SEC Form 4)
- Director Shelton Damion was granted 9,938,151 shares (SEC Form 4)
- Chief Technology Officer Velagapudi Prasanna was granted 3,680,797 stock options (SEC Form 4)
- Chief Financial Officer Beer Michael Thomas was granted 2,576,560 shares (SEC Form 4)
- Chief Executive Officer Johnson Margaret L was granted 347,790 shares (SEC Form 4)
- Chief Robot Officer Hurst Jonathan was granted 12,422,709 shares (SEC Form 4)
- Chief Hardware Officer Marroquin Marco was granted 2,300,498 stock options (SEC Form 4)
- President Diez Daniel was granted 3,220,699 stock options (SEC Form 4)
- SEC Form 3 filed by new insider Hunter Jennifer
Latest OXSQ
- SEC Form 10-Q filed by Oxford Square Capital Corp.
- Oxford Square Capital Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Oxford Square Capital Corp. Announces Net Asset Value and Selected Financial Results for the Quarter Ended September 30, 2026 and Declaration of Distributions on Common Stock for the Months Ending January 31, February 28, and March 31, 2027
- Oxford Square Capital Corp. Schedules Third Quarter 2026 Earnings Release and Conference Call for October 30, 2026
- Oxford Square Capital Corp. filed SEC Form 8-K: Other Events
- SEC Form N-23C-2 filed by Oxford Square Capital Corp.
- Director Novak Steven P sold $6,775 worth of shares (5,000 units at $1.35) (SEC Form 4)
- Oxford Square Capital Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 10-Q filed by Oxford Square Capital Corp.
- Oxford Square Capital Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits